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A B S T R A C T
Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological diseases such as
Alzheimer's disease and multiple sclerosis. To use atrophy rate as a reliable clinical biomarker and to increase
statistical power in clinical treatment trials, measurement variability needs to be minimized. Among other
sources, systematic diﬀerences between diﬀerent MR scanners are suspected to contribute to this variability. In
this study we developed and performed initial validation tests of an MR-compatible phantom and analysis
software for robust and reliable evaluation of the brain volume loss. The phantom contained three inﬂatable
models of brain structures, i.e. cerebral hemisphere, putamen, and caudate nucleus. Software to reliably quantify
volumes form the phantom images was also developed. To validate the method, the phantom was imaged using
3D T1-weighted protocols at three clinical 3T MR scanners from diﬀerent vendors. Calculated volume change
from MRI was compared with the known applied volume change using ICC and mean absolute diﬀerence. As
assessed by the ICC, the agreement between our developed software and the applied volume change for diﬀerent
structures ranged from 0.999–1 for hemisphere, 0.976–0.998 for putamen, and 0.985–0.999 for caudate nucleus.
The mean absolute diﬀerences between measured and applied volume change were 109–332 μL for hemisphere,
2.9–11.9 μL for putamen, and 2.2–10.1 μL for caudate nucleus. This method oﬀers a reliable and robust mea-
surement of volume change using MR images and could potentially be used to standardize clinical measurement
of atrophy rates.
1. Introduction
Neurodegeneration is a persistent problem in multiple sclerosis
(MS) and some other diseases like Alzheimer's disease (AD). In MS, new
treatments are being developed to slow down or prevent this neuro-
degeneration. An accessible in vivo surrogate of neurodegeneration is
brain atrophy, i.e. brain volume loss, which can be measured using
magnetic resonance imaging (MRI). However, measurement variability
is substantial; among other factors, diﬀerences between MRI scanners
introduce unwanted variability of atrophy measures. Studies in MS
observed diﬀerent volumes and volume changes for two diﬀerent
scanners using similar or even identical acquisition parameters
(Durand-Dubief et al., 2012), diﬀerences in global brain tissue volumes
and cortical thickness were found between three diﬀerent 3-Tesla MR
scanners (Biberacher et al., 2016), and even diﬀerent whole-brain vo-
lumes between two scanners of the exact same type with identical
imaging protocols (Takao et al., 2011).
Unwanted scanner or acquisition protocol dependent variability of
atrophy rates directly aﬀects the statistical power of multi-center
treatment trials. Moreover, it hampers the use of monitoring of atrophy
progression in individual patients in the clinical setting. This is espe-
cially problematic in diseases like MS in which the typical annual rate
of brain volume loss is only about 0.5–1% (De Stefano et al., 2016).
In MRI, imaging phantoms have been widely used for quality con-
trol as well as for detecting geometrical distortions (Chen et al., 2004;
Ihalainen et al., 2011; Vassiliou et al., 2016; Wang et al., 2004a,
2004b). To our knowledge, no application has yet been published in
which imaging phantoms are used to standardize measurements of
brain atrophy rates between scanners and acquisition protocols.
In this study we aimed to develop a phantom for standardizing
measurements of volume change between diﬀerent scanners. This
works by scanning the phantom at each scanner/site independently,
and derive a calibration function speciﬁc to the scanner and acquisition
protocol used. Therefore, the resulting calibration is supposed to be
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scanner-speciﬁc which takes into account a couple of sources of
variability such as hardware, ﬁeld strength and pulse sequence type.
The method makes use of an imaging phantom containing three in-
ﬂatable structures to which volume change can be applied in a highly
controlled way. The phantom structures resemble three brain struc-
tures, i.e. hemisphere, putamen and caudate nucleus. In this initial
validation study, the phantom is imaged at various known set volume
changes, and then for each structure the volume change is quantiﬁed
from the phantom MR images using dedicated segmentation software.
2. Materials and methods
2.1. Phantom development
The MRI phantom contains inﬂatable structures equipped with a
precise volume change system (Fig. 1). The phantom contains three
brain structures: a cerebral hemisphere, putamen, and caudate nucleus.
The hemisphere model was created by scanning a post-mortem healthy
brain using a surface 3D scanner (Artec Spider, Arc 3D). The models of
putamen and caudate nucleus were generated from MR images of
healthy control subjects using FSL-FIRST (Patenaude et al., 2011).
Using these models, molds of all three structures were 3D-printed by
ZP151 powder (3D systems). Then, the molds were repeatedly dipped
into pre-vulcanized latex rubber (pvs-elastica, FromX) to reach a
homogenized thickness. Finally, the molds were dissolved in water and
phantoms remained. All three structures were attached on a nylon plate
for stabilization and embedded in a 3D-printed cylinder made by
plexiglass. Syringes (Hamilton®, Switzerland) of 100mL and 100 μL
were incorporated with a custom-made stainless steel plunger with a
ﬁnely bored syringe barrel to change the volume in the hemisphere and
the small structures, respectively.
2.2. MR imaging
To validate the method, the phantom was imaged at three diﬀerent
clinical 3 T MR scanners (GE, Toshiba and Philips) using a standard
clinical 3D gradient echo sequence available at each scanner with voxel
volumes 1–1.2 μL. To eliminate any signal originating from the latex
material constituting the inﬂatable structures, the clinical protocol was
adjusted by a suitable choice of echo time (TE) and repetition time
(TR). Other parameters remained unchanged. For example, at each
scanner, we used the k-space ﬁlters (Fermi at GE, NL2:7* k-space LSI
(linear space invariant) only at Toshiba, and no ﬁlters at Philips) which
were already used in the clinic to get the best image qualities. Scanner
and pulse sequence parameters are given in Table 1. Typical phantom
MR images on Toshiba are shown in Fig. 2.
2.3. Volume change
In each scanning session, ﬁve volume changes were applied to each
of the three structures as indicated in Table 2. The volume changes
were applied as integer multiples of the full rotation of the precision
screw controlling the syringe. They were chosen to range between
about 1% - 5% of the volume of each structure. Because the caudate
nucleus and putamen are of comparable size, the same amount of vo-
lume changes were applied to them. For the hemisphere, the applied
volume changes were chosen much larger than for the two small
structures. Note that the volumes of all three structures were increased
Fig. 1. (a) Side-view and (b) top-view of the phantom, with (c) the volume change system and (d) the complete device. Each structure had inlet and outlet valves to
ﬁll them up with water and to make them air-free, respectively. Rigid tubes (VYGON) of inner and outer diameter of 1mm and 2mm, respectively, were used to
connect structures to the volume change system. All structures are mounted in an oval-shaped 3D-printed housing (PA2200, EOS SLS).
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simultaneously as indicated in Table 2, to maximize eﬃciency of
scanning. For the analysis, step number ﬁve was taken as a reference
volume to calculate the volume decrease towards baseline.
2.4. Image analysis
We developed a segmentation software to measure the volume
changes from the MR images of the phantom. Note that the software
operates on a single 3D image, and quantiﬁes the water volume inside
the structure of interest for that image. Volume changes between steps
in a phantom measurement series are then quantiﬁed by subtracting the
calculated volumes, rather than being quantiﬁed directly by our soft-
ware.
Fig. 3 shows a diagram of the image analysis pipeline. The ﬁnal
output of the software is the volume of water inside the structure of
interest, which is quantiﬁed by integrating the voxel-wise partial vo-
lume estimates of water across the interior of the structure, including its
internal latex-water boundary voxels. First, the images were corrected
for intensity non-uniformity using nonparametric non-uniform intensity
normalization (N3) (Sled et al., 1998). A spline distance of 50mm and a
full width at half maximum (FWHM) value of 0.05 were used. The small
FWHM value was chosen to favour accuracy over speed. Because some
Gibbs ringing is present in our images, peak values were adjusted as
follows. First, the mean and standard deviation of the water inside the
hemisphere was calculated. Then inside the area that is considered to be
surely water, voxels with intensity higher than the median plus 3 times
the standard deviation were reduced to the square root above this cut-
oﬀ level. Because latex and nylon give very low signal, we improved
their contrast with the background by adding to the intensity of every
voxel inside the housing (i.e., also including the water voxels) 0.5 times
the mean intensity of the water inside the core of the hemisphere.
Next, images were prepared to perform FSL-FAST partial volume
estimation. FSL-FAST models voxel intensities with 3 Gaussian dis-
tributions and noise. Without additional pre-processing, FSL-FAST may
treat the nylon and latex material as noise because (i) only a small
portion of voxels in the image contain nylon or latex and (ii) the in-
tensity distribution of these voxels does not match a Gaussian dis-
tribution due to the relatively high number of partial volume voxels.
Therefore, we added areas of voxels with the same intensity as the latex
(“virtual latex”). In order not to inﬂuence the partial volume estimates
(PVEs) in the boundary between water and real latex, we added this
(virtual) extra latex well away from the real latex. Subsequently, FSL-
FAST was run without bias ﬁeld correction. Finally, to correctly esti-
mate volumes, the class of the virtual latex was replaced with the water
class.
2.5. Statistical analysis
To determine the reliability of our measured volume changes,
measured volume changed were compared with the applied volume
changes using interclass correlation coeﬃcient (ICC) with the two-way
mixed model for absolute agreement. Furthermore, mean absolute
diﬀerences (MAD) between measured and applied volume changes
were calculated across each phantom measurement series. For both
statistics, SPSS software version 22 (IBM) was used.
3. Results
3.1. Phantom validation
A representative MR image of the phantom for a given volume is
shown in Fig. 2. To validate the accuracy of the volume change system
and the developed segmentation software, the true applied volume
changes versus measured volume changes are plotted in Fig. 4. As seen
in this ﬁgure, the measured data showed a perfect agreement with the
applied volume changes.
Table 1
Scanner and pulse sequence parameters for the three scanners used.
Vendor GE Philips Toshiba
Model MR750 Ingenuity Titan
Field strength (T) 3 3 3
Coil type 8-channel head
coil
8-channel head
coil
32-channel head
coil
Sequence type FSPGR FEE FEE
TR (ms) 8.21 7.9 5.7
TE (ms) 3.2 4.5 2.4
Flip angle (degrees) 12 8 5
Acquisition matrix 256*256 256*256 256*256
Voxel size (mm) 1×1×1 1×1×1 1×1.2× 1
Slab orientation sagittal sagittal sagittal
Number of slices 140 140 140
Parallel imaging? Yes Yes Yes
Fig. 2. Representative MR images of the hemisphere, putamen, and caudate nucleus phantoms in (a) axial, (b) coronal and (c) sagittal plane as obtained on Toshiba
Titan.
Table 2
Applied volume changes of diﬀerent structures at diﬀerent steps.
Step Caudate nucleus
volume-change (μL)
Putamen volume-
change (μL)
Hemisphere volume-
change (mL)
Baseline 0 0 0
1 26.46 26.46 3.332
2 52.92 52.92 6.665
3 79.38 79.38 9.998
4 105.84 105.84 13.330
5 132.30 132.30 16.663
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Fig. 3. Diagram of the image analysis pipeline to estimate the volumes of the hemisphere, putamen and caudate nucleus. Brieﬂy, the software includes correction for
intensity non-uniformity using N3, Gibbs ringing artifact removal, introduction of an artiﬁcial (“virtual”) latex component to balance the classes in the subsequent
FSL-FAST segmentation, and quantiﬁcation of total internal volume of each structure from the PVE values obtained from FSL-FAST. Red-to-yellow color bar indicates
the water PVE.
Fig. 4. Applied versus measured volume change at three diﬀerent scanners for (top row) hemisphere, (middle row) caudate nucleus, and (bottom row) putamen. The
green dotted line represents the identity line.
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3.2. ICC and mean absolute diﬀerences
Table 3 reports the ICC for absolute agreement and MAD, for the
three brain structures. ICC values indicate that agreement between
applied and measured volume changes is excellent. The MAD data also
shows that deviation of the measured volume changes from the mean
change are relatively negligible compared to the applied volume
changes.
4. Discussion
In this study we developed and validated a phantom and analysis
software to induce and measure volume change of models of brain
structures. The ICCs revealed a very strong agreement between our
developed method and the applied volume change. Therefore, our
method can potentially oﬀer a reliable and robust tool to standardize
measurements of volume change in clinical trials as well as in clinical
settings.
Despite the importance of brain atrophy measurement in neurolo-
gical conditions such as MS and AD, its clinical use at the individual
subject level is hampered by the large measurement variability (Rocca
et al., 2017). Among other sources of variability such as physiological
eﬀects, between-scanner and between-acquisition protocol diﬀerences
are suspected to contribute importantly (Amiri et al., 2018). For ex-
ample, volume diﬀerences were seen when using two diﬀerent scanners
with similar or even identical acquisition parameters (Durand-Dubief
et al., 2012). In another study performed at three diﬀerent 3-Tesla MR
scanners, signiﬁcant diﬀerences in total lesion volume, global brain
tissue volumes and cortical thickness measures between the scanners
were observed (Biberacher et al., 2016). Even when using identical
imaging protocols, it was found that the whole brain volumes were
signiﬁcantly diﬀerent between two scanners of the exact same type
(Takao et al., 2011). Therefore, to increase statistical power in clinical
trials and to establish atrophy measures as reliable clinical biomarkers,
such scanner-induced eﬀects should be minimized.
To date, some anthropomorphic brain phantoms have been de-
scribed, e.g. by using agar gel and manganese chloride (Altermatt et al.,
2017; Fujimoto et al., 2015),) or using polyvinyl alcohol (PVA) (Chen
et al., 2012). The advantage of the method presented in this paper is
that it would allow standardization of the volume change measure-
ments within and between scanners and acquisition protocols. More-
over, this method can accurately and robustly provide a selected vo-
lume change to mimic e.g. the change typically observed in a certain
disease.
A limitation of this study was that we did not test our method in
vivo. Therefore, an important next step in the development of the
present method would be to investigate translation of this method to a
clinical setting to validate it in patients. In our view, as schematically
illustrated in Fig. 5, the translation to an in vivo setting requires ad-
ditional steps such as (i) the phantom contrast-to-noise ratio (CNR)
should mimic the in vivo CNR and (ii) the image analysis software used
to obtain calibration functions from the phantom images should be si-
milar to that used in the patient studies. This implementation includes
acquiring scans of the phantom on the same day as patient scans while
applying known volume changes to the phantom. This would lead to
calibration factors not only per scanner and acquisition protocol, but
also per day of patient visits. Future studies should investigate whether
scanning the phantom on the same day is necessary. Furthermore, it
would be interesting to use this method to test widely used brain vo-
lume analysis software to assess their accuracy, in a manner compar-
able to the work done by Chen et al. on their PVA phantom (Chen et al.,
2012), and to possibly ﬁnd standardization functions to correct for
them. This would facilitate use of this method to standardize volume
change measurements obtained on diﬀerent scanners and analysed
using speciﬁc analysis methods.
It is known that analysis methods are another source of variability
in volume measurements. A study tested reproducibility of the com-
monly used software package SIENA (Cover et al., 2011). They showed
that the variability of atrophy measurement, obtained from scan and re-
scan of the subjects without repositioning, was of considerable magni-
tude compared to the typical atrophy rates. Interestingly, use of 3-Tesla
instead of 1.5-Tesla MRI did not reduce the error (Cover et al., 2014). It
also has been shown that, for both FSL-FIRST and FreeSurfer, within-
session reproducibility error for measuring 1-year hippocampal volume
change was substantial (Mulder et al., 2014). A recent study (Cover
et al., 2016) showed that reproducibility of 1-year volume change
highly depends on the image analysis method, which aﬀects the sta-
tistical power and required sample sizes in clinical trials. Therefore,
next to the scanner-induced variabilities, the analysis software should
also be considered as an important source of variability in measuring
brain volume change in vivo. Even for in vivo measurements that are
standardized according to the ﬁnal proposed clinical method, such
variability of the in vivo analysis software would remain an issue. Of
note, the analysis software that we developed provides high accuracy in
the measurement of the phantom volume change, thus adding only
minimal error.
In conclusion, we demonstrated the feasibility of producing
Table 3
ICC and MAD for all three brain structures.
Hemisphere Putamen Caudate nucleus
ICCa MADb (mL) ICC MAD (μL) ICC MAD (μL)
GE 0.999 0.3322 0.998 2.9 0.999 2.2
Toshiba 1.000 0.1089 0.994 5.5 0.997 3.7
Philips 1.000 0.2612 0.976 11.9 0.985 10.1
a ICC= Interclass correlation coeﬃcient.
b MAD=Mean absolute diﬀerence; voxel sizes: 1 μL for GE and Philips and
1.2 μL for Toshiba.
Fig. 5. Scheme of the phantom clinical implementation for “true volume change” calculation.
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inﬂatable brain phantoms, and were able to adjust the volume of such a
phantom in a controlled and precise way. Future studies should im-
plement and validate the clinical application of this phantom for stan-
dardizing atrophy measurements.
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